Изработка на уеб сайт от Web IT Solutions


Portfolio company

United States

Sector: Medical Devices & Diagnostics

Vortex provides an easy-to-use, label-free, sample preparation free, benchtop solution for routine isolation and purification of CTCs from your liquid biopsy samples.

Vortex mission is to be the innovation leader in Circulating Tumour Cell (CTC) capture technology that improves therapeutic decisions and saves lives. This exciting area is providing critical information from research to the clinic, causing a major shift in how cancer can be treated and monitored.

The combination of targeted therapies and precise diagnostics is allowing for the era of personalized medicine to emerge. The capture and enrichment of circulating tumour cells is going to be a critical element of targeted companion diagnostics. We believe our next generation CTC capture system will allow the full potential of CTCs to be realized.

Originally a spin-out from University of California, Los Angeles, Vortex is now dually based in Cambridge, UK and the Bay Area, US, with a growing international customer base using its automated VTX-1 instrument and generating recurring revenues from disposable cartridges.


Investing in start-ups and early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution. It should be done only as part of a diversified portfolio. Any investments are targeted exclusively at investors who understand the risks of investing in early-stage businesses and can make their own investment decisions. Any pitches for investment are not offers to the public. Investments made in investee companies via funds managed by Sapphire Capital Partners LLP are not covered by the Financial Services Compensation Scheme (FSCS). For more details, please contact us or refer to their website: https://www.fscs.org.uk


Don’t invest unless you’re prepared to lose all the money you invest. This is a high risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.